Preventing Cognitive Decline

Rhonda Patrick: Vitamin D supplementation associated with significantly lower dementia incidence

Rhonda Patrick

“Vitamin D supplementation is associated with substantially lower dementia risk, with 84% of supplement users remaining dementia- free over five years compared to 68% of non-users. This protective effect holds even for individuals who already have mild cognitive impairment, suggesting vitamin D may slow or prevent progression to dementia. Notably, the benefit is sex- dependent: women who supplemented experienced nearly 50% lower dementia incidence compared to non-supplementing women, while men saw a 26% reduction.”

Attia: APOE4 genetic risk and the case for early cognitive intervention

Peter Attia

“The APOE4 isoform differs from wild-type APOE by just one amino acid, yet this small change dramatically alters the protein's 3D conformation, impairing cholesterol transport, promoting neuroinflammation, and disrupting beta-amyloid chaperoning — a cascade of mechanisms that substantially elevates Alzheimer's risk. Knowing one's APOE4 carrier status early is clinically valuable because it allows individuals to address exacerbating risk factors before disease progression begins, improving long- term outcomes.”

Matt Walker & Rhonda Patrick: Sleep deprivation as a root cause of Alzheimer's and chronic disease

Rhonda Patrick

“Chronic sleep loss disrupts the autonomic nervous system, which governs hormonal systems and drives the cascade of deficits leading to major diseases. Every leading cause of death in the developed world has causal links to insufficient sleep, with Alzheimer's disease being a prominent example under active research.”

Attia: Environmental disconnection and social isolation accelerate cognitive decline

Peter Attia

“Removing individuals from familiar environments and cutting off social interaction is one of the fastest known triggers of cognitive impairment and accelerated decline. The amyloid beta hypothesis of Alzheimer's is complicated by significant discordance between amyloid burden found postmortem and the severity of dementia symptoms experienced during life, suggesting amyloid alone does not fully explain the disease.”

Rhonda Patrick: Moderate alcohol consumption associated with reduced dementia risk in older adults

Rhonda Patrick

“A meta-analysis of over 15 international studies in adults over 60 found that occasional and light-to-moderate drinkers had a 22% lower risk of developing dementia compared to abstainers, while moderate-to-heavy drinkers showed an even greater 30% risk reduction. The study controlled for the 'sick quitter effect' by separating lifelong abstainers from those who stopped drinking due to illness. However, when comparing only current drinkers, the differences in dementia risk across drinking categories were no longer statistically significant, suggesting the protective signal may be nuanced.”

Rhonda Patrick: APOE4 genotype dramatically amplifies dementia risk with alcohol consumption

Rhonda Patrick

“Carrying the APOE4 allele significantly elevates baseline Alzheimer's risk (2x for one copy, up to 12x for two copies), and alcohol consumption further compounds this risk in carriers. Even infrequent drinking (less than once a month) raises dementia risk 2.3-fold in APOE4 carriers compared to non- drinkers with the same genotype, while drinking several times per month elevates Alzheimer's risk 3.6-fold. This gene- environment interaction suggests that APOE4 carriers should treat alcohol as a particularly high-risk factor for cognitive decline.”

Rhonda Patrick: ApoE4 genotype dramatically raises Alzheimer's risk, making early screening essential

Rhonda Patrick

“Carrying one copy of the ApoE4 allele raises lifetime Alzheimer's risk to roughly 30%, while two copies push risk above 50%—and up to 90% in some studies—compared to just 9% for non-carriers. Because actionable risk factors like homocysteine, methylation status, and inflammation can be identified and addressed, Alzheimer's is increasingly considered a preventable disease. Everyone over 45 should undergo baseline cognitive and biomarker screening ('cognoscopy') to identify their personal risk profile before symptoms emerge.”

Rhonda Patrick & Dale Bredesen: High copper-to-zinc ratio as a biomarker for toxic Alzheimer's

Rhonda Patrick

“Elevated copper-to-zinc ratios have been associated with dementia for over 30 years, likely because copper generates free radicals (similar to iron) that contribute to oxidative stress in the brain. Zinc, by contrast, plays critical structural roles in hundreds of enzymes involved in insulin function, immune responses, and cognition. An imbalanced copper-zinc ratio may serve as a biomarker for the toxic-insult subtype of Alzheimer's disease (Type 3), signaling underlying metabolic and oxidative dysfunction rather than directly displacing zinc in enzymatic roles.”

Rhonda Patrick: ApoE4 genotype, phenotype expression, and Alzheimer's risk

Rhonda Patrick

“Carrying an ApoE4 allele is a significant genetic risk factor for Alzheimer's disease, and both Rhonda Patrick and Peter Attia suggest the phenotype — specifically the amount of ApoE expressed — may matter more than genotype alone. Diet-related factors such as saturated versus polyunsaturated fat intake interact with ApoE4 status, making dietary choices particularly relevant for carriers. Patrick notes she is actively researching ApoE4's mechanistic role in Alzheimer's, reflecting the gene's centrality to cognitive decline prevention strategies.”

Attia & Patrick: ApoE genotype vs. phenotype in Alzheimer's risk

Rhonda Patrick

“ApoE4 genotype significantly elevates Alzheimer's risk—3/4 carriers face roughly 2x the risk of 3/3 individuals, while 4/4 carriers face 10-20x higher risk. However, Peter Attia argues that the amount of ApoE protein expressed (the phenotype) may matter more than the genotype itself, suggesting that measuring circulating ApoE levels could be more clinically meaningful than genotyping alone. Notably, the majority of Alzheimer's cases still occur in 3/3 individuals, underscoring that ApoE4 is a risk factor, not a deterministic cause.”

Rhonda Patrick: APOE4 genotype and elevated Alzheimer's risk

Rhonda Patrick

“The APOE4 allele significantly increases the risk of Alzheimer's disease and dementia, with an earlier age of onset in affected populations. Approximately 15–25% of people carry one copy of APOE4 and 2–5% carry two copies, making this one of the most important genetic risk factors for cognitive decline. APOE encodes a protein that combines lipids into lipoproteins, and its E4 variant disrupts normal lipid metabolism in ways that contribute to neurodegeneration. Understanding one's APOE genotype is critical context for interpreting lifestyle and dietary intervention studies on dementia prevention.”

Rhonda Patrick: Alzheimer's as a neuronal energy failure driven by insulin resistance

Rhonda Patrick

“Alzheimer's disease may be fundamentally a neuronal energy problem rooted in insulin resistance and impaired glucose metabolism through the pyruvate dehydrogenase/Krebs cycle pathway, with tau tangles and synaptic loss as downstream byproducts rather than primary drivers. Evidence from animal models shows that transient correction via simultaneous glucose/insulin administration or exogenous ketone bodies (BHB) can reverse signs and symptoms by bypassing the metabolic block. This framing supports clinical approaches such as very-low- glycemic-index diets combined with MCT oil to induce mild ketosis as a strategy for early cognitive decline prevention.”

Peter Attia: Alzheimer's rising incidence points to environmental triggers, not just aging

Rhonda Patrick

“Alzheimer's disease incidence has increased approximately 2.5% per year over the last 50 years, while longevity has grown only 0.6% per year — a gap too large to be explained by longer lifespans or improved diagnosis alone. This divergence is compelling evidence that environmental or lifestyle factors are actively driving Alzheimer's disease, rather than it being an inevitable consequence of aging. Unlike cardiovascular disease, there are no effective pharmacological interventions for Alzheimer's, making identification of these modifiable environmental triggers critical for prevention.”

Rhonda Patrick: Alzheimer's as a neuronal energy failure driven by insulin resistance

Rhonda Patrick

“Alzheimer's disease is fundamentally a neuronal energy problem rooted in insulin resistance and impaired glucose metabolism through pyruvate dehydrogenase into the Krebs cycle, with tau tangles and synaptic dysfunction as downstream byproducts rather than primary drivers. Animal model evidence shows that exogenous BHB can bypass the metabolic block and transiently reverse signs and symptoms, supporting ketone-based interventions. Clinical approaches combining very-low-glycemic-index diets with MCT oil to induce mild ketosis—without requiring a strict ketogenic diet—have shown promising results in early cognitive decline.”

Bredesen: Alzheimer's defined by amyloid plaques and tau tangles as the leading cause of cognitive decline

Rhonda Patrick

“Cognitive decline is very common, and Alzheimer's disease is its most frequent cause, ultimately leading to dementia. Alzheimer's is pathologically defined by the presence of amyloid plaques and phosphorylated tau tangles in the brain. Understanding these distinguishing features is foundational to Dr. Bredesen's multi- pronged protocol aimed at preventing and reversing mild cognitive impairment.”

Bredesen: Alzheimer's pathological hallmarks don't explain causation

Rhonda Patrick

“Alzheimer's disease is defined by the presence of amyloid plaques and phosphorylated tau tangles in the brain, but these pathological hallmarks describe what the disease looks like rather than why it develops. Understanding the underlying causes of cognitive decline requires looking beyond these markers to the mechanisms that drive their formation.”

Attia: APOE4 increases Alzheimer's susceptibility through impaired brain cholesterol transport

Peter Attia

“The APOE4 variant differs from APOE3 by just a single amino acid substitution, which alters the shape of the apoE protein and reduces its ability to transfer cholesterol from astrocytes to neurons. This impaired lipid transport mechanism explains why APOE4 carriers have greater susceptibility to Alzheimer's disease, though the gene is neither causative nor deterministic. Crucially, carriers of one or two APOE4 alleles must work harder on all other modifiable risk factors to offset this inherited vulnerability.”

Rhonda Patrick: Fixing blood vessels may delay dementia symptoms by years

Rhonda Patrick

“Vascular dysfunction, including blood-brain barrier leakiness and pericyte detachment, is an early and detectable event in cognitive decline, particularly in APOE4 carriers. Intervening to repair blood vessel integrity before neurodegeneration sets in may not cure Alzheimer's disease but could meaningfully postpone symptoms by a decade or more, representing a significant quality-of-life benefit. Screening for vascular biomarkers could help identify individuals who would benefit most from such targeted interventions.”

Rhonda Patrick & Dale Bredesen: Zinc deficiency and copper-zinc imbalance in toxic-subtype Alzheimer's

Rhonda Patrick

“A metabolic subtype of Alzheimer's disease (Type 3, 'toxic') is characterized by low serum zinc, elevated copper-to-zinc ratios, and low triglycerides. Because copper and zinc compete for absorption, excess copper is often associated with zinc depletion, and zinc deficiency is already widespread globally. These mineral imbalances may represent actionable biomarkers for identifying and potentially addressing this Alzheimer's subtype.”

257 ‒ Cognitive decline, neurodegeneration, and head injuries: mitigation and prevention strategies

Peter Attia

“preventing cognitive decline there was a big met analysis done by uh jintai you who's a professor in Shanghai looking at all the different potentially modifiable factors for cognitive decline the two most important protective ones were early in life education”

The Most Effective Weight Training, Cardio & Nutrition for Women | Dr. Lauren Colenso-Semple

Andrew Huberman

“…because the data to date doesn't support the use of it for preventing cognitive decline or preventing cardiovascular disease. And there's a lot of messaging out there that is sort of telling women if you don't take hormone therapy you're doomed. And that's no”

257 ‒ Cognitive decline, neurodegeneration, and head injuries: mitigation and prevention strategies

Peter Attia

“…of a societal effects but when you think broadly about how cognitive function declines with age it seems to mirror very closely the amount of demand that we put on our brains and again across like how Society is constructed because cognitive function essentia”

Dr. Dale Bredesen on Preventing and Reversing Alzheimer's Disease

Rhonda Patrick

“…but what was really, really robust was the improvements in cognitive function and brain aging and it was just, you know, hands down like clear that that diet really helped delay brain aging. And so, you know, of course, those weren't ApoE4 positive mice but..”

Dr. Dale Bredesen on Preventing and Reversing Alzheimer's Disease

Rhonda Patrick

“…back between these different states, and the people who had cognitive decline are poor at getting rid, they're literally keeping this amyloid around. And he looked at their M1 to M2 ratios, essentially inflammation to resolution, he saw two patterns. The peopl”

Tim Ferriss on Ketosis, Microbiome, Lyme Disease, and Biomarkers

Rhonda Patrick

“…training, much more effective bang for the book in not only preventing lean muscle tissue loss but increasing muscle gain than say most types of internal training, even if you're temporarily spiking certain hormones. But that's also because I hate doing endura”

The Optimal Creatine Protocol for Strength, Brain, and Longevity | Darren Candow, PhD

Rhonda Patrick

“…scue the effects to give a significant effect we don't know preventing would be the number one thing but uh we're starting to do a study in Northern Iowa to look at the effects of creatine now in individuals with cognitive decline um and I believe there's a st”

How to Improve Memory & Focus Using Science Protocols | Dr. Charan Ranganath

Andrew Huberman

“…a number of Dos both in the context of offsetting age relay cognitive decline Alzheimer's but also in terms of how to enhance focus and enhance memory um I want to make make sure that we um touch on a few topics related to memory that a little bit um off the t”